Sodium-glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes

被引:0
|
作者
Zhang, Shujun [1 ,2 ]
Wang, Fen [1 ,2 ]
Xie, Lei [1 ,2 ]
Xu, Jialu [1 ,2 ]
Song, Xiaoqing [1 ,2 ]
Tao, Jing [1 ,2 ]
Chen, Juan [3 ]
Ma, Delin [1 ,2 ]
Yu, Xuefeng [1 ,2 ]
Shi, Xiaoli [1 ,2 ]
Yang, Yan [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Hubei, Peoples R China
[2] Branch Natl Clin Res Ctr Metab Dis, Wuhan, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China
关键词
Cognitive impairment; Henagliflozin; Type; 2; diabetes; DYSFUNCTION; INSULIN;
D O I
10.1111/jdi.14306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction: To assess whether the sodium-glucose cotransporter 2 inhibitor, henagliflozin, improves cognitive impairment in patients with type 2 diabetes. Materials and Methods: We carried out a prospective study on 290 patients with type 2 diabetes and cognitive impairment. Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels were used to assess cognition. The association between henagliflozin use and changes in cognition was examined using multivariable logistic regression analysis. Results: Montreal Cognitive Assessment scores at enrollment and after 6 months were 21 (interquartile range [IQR]19-23) versus 22 (IQR 20-25; P < 0.0001) in all patients, 21 (IQR 19-23) versus 24 (IQR 22-26; P < 0.0001) in the henagliflozin group and 21 (IQR 19-22) versus 21 (IQR 19-23; P > 0.05) in the non-sodium-glucose cotransporter 2 inhibitor group. Logistic regression analysis showed that henagliflozin treatment was associated with Montreal Cognitive Assessment score improvement independent of potential confounders (odds ratio [OR] 3.670, 95% confidence interval [CI] 2.224-6.056, P < 0.0001). Additionally, plasma phosphorylated tau181 levels significantly decreased at 6-month follow up in all patients (OR 11.5, 95% CI 9.9-13.7 vs OR 10.1, 95% CI 7.8-12.9, P < 0.0001) and in the henagliflozin group (OR 11.5, 95% CI 10.3-13.0 vs OR 9.2, 95% CI 7.1-10.7, P < 0.0001), but not in the non-sodium-glucose cotransporter 2 inhibitor group. Henagliflozin treatment was independently associated with decreased phosphorylated tau181 levels (OR 3.670, 95% CI 1.598-4.213, P < 0.0001). Conclusions: Henagliflozin treatment was independently associated with improvements in Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels, indicating significant beneficial effects on cognitive impairment in patients with type 2 diabetes.
引用
收藏
页码:1596 / 1603
页数:8
相关论文
共 50 条
  • [21] Empagliflozin: A sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
    Dixit, Divisha
    Yoon, Youngmin
    Volino, Lucio R.
    Mansukhani, Rupal Patel
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (22) : 1943 - 1954
  • [22] Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
    Scheen, Andre J.
    NATURE REVIEWS ENDOCRINOLOGY, 2020, 16 (10) : 556 - 577
  • [23] Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
    Hedrington, Maka S.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (04) : 613 - 623
  • [24] Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
    Vivian, Eva
    DIABETES EDUCATOR, 2015, 41 : 5S - 18S
  • [25] The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
    Steen, Oren
    Goldenberg, Ronald M.
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (05) : 517 - 523
  • [26] Real-Life Evaluation of Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes
    Stougaard, Elisabeth Buur
    Kristensen, Peter L.
    Kielgast, Urd
    Andersen, Henrik U.
    Hamid, Yasmin H.
    Gaede, Peter
    Sondergaard, Esben
    Dorflinger, Gry
    Fjeldborg, Karen K.
    Hansen, Klavs W.
    Thomsen, Henrik H.
    Al-Imari, Thuraya
    Roder, Michael
    Rossing, Peter
    Persson, Frederik
    DIABETES, 2022, 71
  • [27] Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
    Ferrannini, Ele
    Baldi, Simona
    Frascerra, Silvia
    Astiarraga, Brenno
    Heise, Tim
    Bizzotto, Roberto
    Mari, Andrea
    Pieber, Thomas R.
    Muscelli, Elza
    DIABETES, 2016, 65 (05) : 1190 - 1195
  • [28] Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk
    Liakos A.
    Bekiari E.
    Tsapas A.
    Current Cardiovascular Risk Reports, 2016, 10 (6)
  • [29] The gender gap in prescription pattern of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes
    Hammer, A.
    Hofer, F.
    Kazem, N.
    Koller, L.
    Steinacher, E.
    Niessner, A.
    Sulzgruber, P.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2691 - 2691
  • [30] Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
    Xie, Yan
    Bowe, Benjamin
    Gibson, Andrew K.
    McGill, Janet B.
    Maddukuri, Geetha
    Al-Aly, Ziyad
    JAMA INTERNAL MEDICINE, 2021, 181 (08) : 1043 - 1053